Explore new findings on ovarian cancer and how blocking focal adhesion kinase can enhance immune response in treatment.

HIGHLIGHTS Amplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conferenceData showing narmafotinib activity in preclinical ...

Ovarian cancer treatment faces challenges with high relapse and drug resistance rates, despite initial chemotherapy effectiveness. Cytokines like IL-6 and IL-11 are associated with complex tumor ...

Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous ...

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this ...

Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination ...

The experimental drug is an ultrasensitive version of CAR-T therapies, which have already revolutionized the treatment of ...

Liraltagene autoleucel, or lira-cel, targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells, but not in ...

(Reuters) -AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the UK at a list price matching that in the U.S. President Donald Trump has been demanding that drugmakers align ...

Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, ...

No matter how hard this is, I still recommend clinical trials. Not as a last resort, but as an important option when weighing treatment choices. I don’t know what choice I’ll make, but I’m thankful ...